Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment

NCT02802345 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02802345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02802345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2016
Completion date
April 13, 2018
Enrollment
274 (actual)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis